Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib renal impairment pharmacokinetics study in advanced solid tumors
NL-OMON40271Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaparib in Non-hematologic malignancy (3 arms), sponsored by AstraZeneca. Primary endpoints: Maximum plasma concentration, Time to maximum plasma concentration and 7 more. Started Jan 2014; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on NL-OMON40271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40271.